Jesper van Eck van der Sluijs

5PUBLICATIONS
28CO-AUTHORS
Molecular targetsPredictive and prognostic markersApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Cultural responsiveness and working with Pacific Peoples communities educationCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (5)

|Apr 03, 2026
Sialic acid cis-ligand dynamics modulate Siglec-7 and -9 function and affect Siglec-7/9 co-blockade to potentiate natural killer cell anti-tumor activity.

Jesper van Eck van der Sluijs, Anne H C Valk, Eline J H van Houtum

|Sep 09, 2024
Siglec-7 and Siglec-9 expression in primary triple negative and oestrogen receptor positive breast cancer and in vitro signalling.

Eline Jh van Houtum, Anne Hc Valk, Daniel Granado

|Sep 20, 2023
Human CD34+-derived complete plasmacytoid and conventional dendritic cell vaccine effectively induces antigen-specific CD8+ T cell and NK cell responses in vitro and in vivo.

Jesper van Eck van der Sluijs, Diede van Ens, Jolanda Brummelman

|Aug 23, 2023
Saponin-based adjuvants enhance antigen cross-presentation in human CD11c+ CD1c+ CD5- CD163+ conventional type 2 dendritic cells.

Nataschja I Ho, Lisa G M Huis In 't Veld, Jesper van Eck van der Sluijs

|Apr 02, 2021
Clinically applicable CD34+-derived blood dendritic cell subsets exhibit key subset-specific features and potently boost anti-tumor T and NK cell responses.

Jesper van Eck van der Sluijs, Diede van Ens, Soley Thordardottir

Pageof 1

Frequent Collaborators

3 joint publications

Gosse J Adema

3 joint publications

Harry Dolstra

2 joint publications

Diede van Ens

2 joint publications

Willemijn Hobo